CD45dimCD34+CD38−CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia

• Main Authors: Sook-Kyoung Heo, Eui-Kyu Noh, Lan Jeong Ju, Jun Young Sung, Yoo Kyung Jeong, Jaekyung Cheon, Su Jin Koh, Young Joo Min, Yunsuk Choi, Jae-Cheol Jo
• Format: Article
• Language: English
• Published: BMC 2020-04-01
• Series: BMC Cancer
• Subjects: Acute myeloid leukemia; Leukemic stem cells; CD45dimCD34+CD38−CD133+ cells; Prognosis; Immunophenotyping
• Online Access: http://link.springer.com/article/10.1186/s12885-020-06760-1

Abstract Background Leukemia stem cells (LSCs) in play an important role in the initiation, relapse, and progression of acute myeloid leukemia (AML), and in the development of chemotherapeutic drug resistance in AML. Studies regarding the detection of LSCs and the development of novel therapies for targeting them are extensive. The identification of LSCs and targeting therapies for them has been continuously under investigation. Methods We examined the levels of CD45dimCD34+CD38−CD133+ cells in bone marrow samples from patients with hematological malignancies and healthy controls, using four-color flow cytometry. Results Interestingly, the CD45dimCD34+CD38−CD133+ cells were highly expressed in the bone marrow of patients with AML compared to that in healthy controls (HC). Moreover, the proportions of CD45dimCD34+CD38−CD133+ cells were also examined in diverse hematological malignancies, including AML, CML, DLBCL, MM, MDS, HL, ALL, and CLL. LSCs were prominently detected in the BMCs isolated from patients with AML and CML, but rarely in BMCs isolated from patients with DLBCL, MM, MDS, ALL, CLL, and HL. Additionally, the high CD45dimCD34+CD38−CD133+ cell counts in AML patients served as a significantly poor risk factor for overall and event free survival. Conclusions Therefore, our results suggest that CD45dimCD34+CD38−CD133+ cells in AML might potentially serve as LSCs. In addition, this cell population might represent a novel therapeutic target in AML.